Positive
Seeking Alpha
yesterday
Edwards Lifesciences: Inflection Incoming, But When?
Edwards Lifesciences Corporation remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and consistent revenue growth. EW's TMTT segment is the fastest-growing area, but margin pressures, stagnating EPS, and declining returns limit near-term upside potential. Despite a robust balance sheet and ongoing share buybacks, EW's valuation appears stretched relative to its growth and industry peers.